Literature DB >> 19695655

Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naïve human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutralization potency and breadth.

Elena Gustchina1, John M Louis, Christian Frisch, Francisco Ylera, Annette Lechner, Carole A Bewley, G Marius Clore.   

Abstract

Previously we reported a broadly HIV-1 neutralizing mini-antibody (Fab 3674) of modest potency that was derived from a human non-immune phage library by panning against the chimeric gp41-derived construct N(CCG)-gp41. This construct presents the N-heptad repeat of the gp41 ectodomain as a stable, helical, disulfide-linked trimer that extends in helical phase from the six-helix bundle of gp41. In this paper, Fab 3674 was subjected to affinity maturation against the N(CCG)-gp41 antigen by targeted diversification of the CDR-H2 loop to generate a panel of Fabs with diverse neutralization activity. Three affinity-matured Fabs selected for further study, Fabs 8060, 8066 and 8068, showed significant increases in both potency and breadth of neutralization against HIV-1 pseudotyped with envelopes of primary isolates from the standard subtype B and C HIV-1 reference panels. The parental Fab 3674 is 10-20-fold less potent in monovalent than bivalent format over the entire B and C panels of HIV-1 pseudotypes. Of note is that the improved neutralization activity of the affinity-matured Fabs relative to the parental Fab 3674 was, on average, significantly greater for the Fabs in monovalent than bivalent format. This suggests that the increased avidity of the Fabs for the target antigen in bivalent format can be partially offset by kinetic and/or steric advantages afforded by the smaller monovalent Fabs. Indeed, the best affinity-matured Fab (8066) in monovalent format ( approximately 50 kDa) was comparable in HIV-1 neutralization potency to the parental Fab 3674 in bivalent format ( approximately 120 kDa) across the subtype B and C reference panels.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19695655      PMCID: PMC2759307          DOI: 10.1016/j.virol.2009.07.019

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  57 in total

1.  Monoclonal antibodies that bind to the core of fusion-active glycoprotein 41.

Authors:  C H Chen; M L Greenberg; D P Bolognesi; T J Matthews
Journal:  AIDS Res Hum Retroviruses       Date:  2000-12-10       Impact factor: 2.205

2.  Protein design of an HIV-1 entry inhibitor.

Authors:  M J Root; M S Kay; P S Kim
Journal:  Science       Date:  2001-02-02       Impact factor: 47.728

3.  Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.

Authors:  D M Eckert; P S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

Review 4.  Mechanisms of viral membrane fusion and its inhibition.

Authors:  D M Eckert; P S Kim
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

5.  Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides.

Authors:  A Knappik; L Ge; A Honegger; P Pack; M Fischer; G Wellnhofer; A Hoess; J Wölle; A Plückthun; B Virnekäs
Journal:  J Mol Biol       Date:  2000-02-11       Impact factor: 5.469

6.  Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.

Authors:  Jacqueline D Reeves; Stephen A Gallo; Navid Ahmad; John L Miamidian; Phoebe E Harvey; Matthew Sharron; Stefan Pohlmann; Jeffrey N Sfakianos; Cynthia A Derdeyn; Robert Blumenthal; Eric Hunter; Robert W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-20       Impact factor: 11.205

7.  Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity.

Authors:  J M Louis; C A Bewley; G M Clore
Journal:  J Biol Chem       Date:  2001-06-19       Impact factor: 5.157

8.  Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Ming Li; Feng Gao; John R Mascola; Leonidas Stamatatos; Victoria R Polonis; Marguerite Koutsoukos; Gerald Voss; Paul Goepfert; Peter Gilbert; Kelli M Greene; Miroslawa Bilska; Denise L Kothe; Jesus F Salazar-Gonzalez; Xiping Wei; Julie M Decker; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

9.  Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41.

Authors:  Carole A Bewley; John M Louis; Rodolfo Ghirlando; G Marius Clore
Journal:  J Biol Chem       Date:  2002-02-21       Impact factor: 5.157

10.  Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates.

Authors:  Hana Golding; Marina Zaitseva; Eve de Rosny; Lisa R King; Jody Manischewitz; Igor Sidorov; Miroslaw K Gorny; Susan Zolla-Pazner; Dimiter S Dimitrov; Carol D Weiss
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more
  13 in total

1.  Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus.

Authors:  Yong Wang; Zhen-Yong Keck; Anasuya Saha; Jinming Xia; Fraser Conrad; Jianlong Lou; Michael Eckart; James D Marks; Steven K H Foung
Journal:  J Biol Chem       Date:  2011-10-14       Impact factor: 5.157

2.  Reversion of somatic mutations of the respiratory syncytial virus-specific human monoclonal antibody Fab19 reveal a direct relationship between association rate and neutralizing potency.

Authors:  John T Bates; Christopher J Keefer; Thomas J Utley; Bruno E Correia; William R Schief; James E Crowe
Journal:  J Immunol       Date:  2013-03-01       Impact factor: 5.422

3.  The C34 Peptide Fusion Inhibitor Binds to the Six-Helix Bundle Core Domain of HIV-1 gp41 by Displacement of the C-Terminal Helical Repeat Region.

Authors:  John M Louis; James L Baber; G Marius Clore
Journal:  Biochemistry       Date:  2015-11-09       Impact factor: 3.162

Review 4.  Phages and HIV-1: from display to interplay.

Authors:  Sylvie Delhalle; Jean-Claude Schmit; Andy Chevigné
Journal:  Int J Mol Sci       Date:  2012-04-13       Impact factor: 6.208

5.  Structural basis of HIV-1 neutralization by affinity matured Fabs directed against the internal trimeric coiled-coil of gp41.

Authors:  Elena Gustchina; Mi Li; John M Louis; D Eric Anderson; John Lloyd; Christian Frisch; Carole A Bewley; Alla Gustchina; Alexander Wlodawer; G Marius Clore
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

6.  Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41.

Authors:  Charles Sabin; Davide Corti; Victor Buzon; Mike S Seaman; David Lutje Hulsik; Andreas Hinz; Fabrizia Vanzetta; Gloria Agatic; Chiara Silacci; Lara Mainetti; Gabriella Scarlatti; Federica Sallusto; Robin Weiss; Antonio Lanzavecchia; Winfried Weissenhorn
Journal:  PLoS Pathog       Date:  2010-11-18       Impact factor: 6.823

7.  Antibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination Strategies.

Authors:  Vincent Holl; Maryse Peressin; Christiane Moog
Journal:  Viruses       Date:  2009-12-15       Impact factor: 5.048

8.  Complexes of neutralizing and non-neutralizing affinity matured Fabs with a mimetic of the internal trimeric coiled-coil of HIV-1 gp41.

Authors:  Elena Gustchina; Mi Li; Rodolfo Ghirlando; Peter Schuck; John M Louis; Jason Pierson; Prashant Rao; Sriram Subramaniam; Alla Gustchina; G Marius Clore; Alexander Wlodawer
Journal:  PLoS One       Date:  2013-11-07       Impact factor: 3.240

9.  Binding of HIV-1 gp41-directed neutralizing and non-neutralizing fragment antibody binding domain (Fab) and single chain variable fragment (ScFv) antibodies to the ectodomain of gp41 in the pre-hairpin and six-helix bundle conformations.

Authors:  John M Louis; Annie Aniana; Katheryn Lohith; Jane M Sayer; Julien Roche; Carole A Bewley; G Marius Clore
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

10.  Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors.

Authors:  Nuria González; Krisha McKee; Rebecca M Lynch; Ivelin S Georgiev; Laura Jimenez; Eulalia Grau; Eloísa Yuste; Peter D Kwong; John R Mascola; José Alcamí
Journal:  PLoS One       Date:  2018-03-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.